Amgen Inc. (AMGN)

183.55
0.05 0.03
NASDAQ : Health Technology
Prev Close 183.60
Open 183.86
Day Low/High 182.68 / 186.12
52 Wk Low/High 152.16 / 201.23
Volume 4.37M
Avg Volume 3.22M
Exchange NASDAQ
Shares Outstanding 721.32M
Market Cap 126.14B
EPS 2.70
P/E Ratio 68.25
Div & Yield 5.28 (2.56%)

Latest News

Amgen Becomes #38 Most Shorted Nasdaq 100 Component, Replacing Charter Communications

Amgen Becomes #38 Most Shorted Nasdaq 100 Component, Replacing Charter Communications

The most recent short interest data has been released for the 01/12/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Biotech, Pharma Stocks Tumble Amid Big Market Sell-Off

Biotech, Pharma Stocks Tumble Amid Big Market Sell-Off

Vertex Pharmaceuticals, Amgen and Johnson and Johnson were among the big movers in the biotech and pharmaceutical sectors.

Cramer vs. Chaikin: Amgen -- Be Careful of This Stock

Cramer vs. Chaikin: Amgen -- Be Careful of This Stock

TheStreet's Jim Cramer and Marc Chaikin, of Chaikin Analytics, spent an hour together at our offices talking all things markets. Listen to the whole conversation below. In the except above, they discuss Amgen and why Chaikin says to be careful of the stock.

The Shifting Price Action Continued Today

The Shifting Price Action Continued Today

The good news is that volatility is increasing. The bad news, for some, is that it moves in both directions.

The Really Big Money Rushes to Super Bowl

The Really Big Money Rushes to Super Bowl

This will be the ninth consecutive year when the big game tops that 100 million-viewers mark.

Amgen Receives CHMP Positive Opinion To Add Updated Overall Survival Data To KYPROLIS® (carfilzomib) Label

Amgen Receives CHMP Positive Opinion To Add Updated Overall Survival Data To KYPROLIS® (carfilzomib) Label

Label Variation to Include Overall Survival Data From Phase 3 ENDEAVOR Trial

Get Ready for Volatility Now: Cramer's 'Mad Money' Recap (Monday 1/29/18)

Get Ready for Volatility Now: Cramer's 'Mad Money' Recap (Monday 1/29/18)

Jim Cramer says watch out for those earnings reports this week, and use any pullback to put some money into a good index fund. You won't regret it.

Cramer: Step Away and Get Your Clients Better Prices

Cramer: Step Away and Get Your Clients Better Prices

You mean to tell me if the buyers walked away for 10 minutes they couldn't get these stocks lower?

Super Bowl of Earnings: Cramer's 'Mad Money' Recap (Friday 1/26/18)

Super Bowl of Earnings: Cramer's 'Mad Money' Recap (Friday 1/26/18)

Politics, Davos, news -- none of it matters as much as earnings. Here's Jim Cramer's game plan for next week.

Amgen Becomes #38 Most Shorted Nasdaq 100 Component, Replacing Charter Communications

The most recent short interest data has been released for the 01/12/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Jim's Daily Rundown

Jim discusses our outlook on Allergan, JPMorgan's investment plan, Microsoft, Constellation Brands, and more!

Amgen Reports Aimovig™ (Erenumab) Met All Primary And Secondary Endpoints In Unique Phase 3b Study In Episodic Migraine Patients Who Have Failed Multiple Prior Preventive Treatments

Amgen Reports Aimovig™ (Erenumab) Met All Primary And Secondary Endpoints In Unique Phase 3b Study In Episodic Migraine Patients Who Have Failed Multiple Prior Preventive Treatments

LIBERTY is the First Migraine Prevention Trial of its Kind Conducted Specifically in Patients Who Have Tried Multiple Therapies Without Success, and are in Need of Additional Treatment Options

European Commission Approves Amgen And Allergan's MVASI® (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer

European Commission Approves Amgen And Allergan's MVASI® (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer

Marketing Authorization Based on Global Development Program Showing MVASI is Highly Similar to Avastin® (Bevacizumab)

FDA Approves Addition Of Overall Survival Data To KYPROLIS® (carfilzomib) Label

FDA Approves Addition Of Overall Survival Data To KYPROLIS® (carfilzomib) Label

Phase 3 Data Showed KYPROLIS and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Velcade® (Bortezomib) and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Overall Survival Analysis From KYPROLIS® (Carfilzomib) Phase 3 ASPIRE Trial Published In The Journal Of Clinical Oncology

Overall Survival Analysis From KYPROLIS® (Carfilzomib) Phase 3 ASPIRE Trial Published In The Journal Of Clinical Oncology

KYPROLIS, Lenalidomide and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Lenalidomide and Dexamethasone Alone in Patients With Relapsed or Refractory Multiple Myeloma

European Medicines Agency Accepts Filing For EVENITY™ (Romosozumab)

European Medicines Agency Accepts Filing For EVENITY™ (Romosozumab)

Application Supported by Phase 3 Data in More Than 11,000 Postmenopausal Women and Men with Osteoporosis at Increased Risk of Fracture

Who Cares About the Jobs Report? Here Are 3 Quick Reasons Stocks Could Skyrocket

Who Cares About the Jobs Report? Here Are 3 Quick Reasons Stocks Could Skyrocket

The outlook for the stock market in 2018 remains strong despite a dour reading on U.S. employment for December.

FDA Approves XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma

FDA Approves XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma

Expansion of Indication Offers Patients a New Treatment Option

Jim's Daily Rundown

In today's video, Jim discusses Danaher, Illinois Tool Works and other industrials, Europe, and the semiconductors.

Jim Cramer: Stocks Are on Fire For Good Reasons

Jim Cramer: Stocks Are on Fire For Good Reasons

Stocks put in broad gains supported by tax cuts, bonuses, a weaker dollar and more.

Best Biotech Stock Trades and Mergers to Watch in 2018

Best Biotech Stock Trades and Mergers to Watch in 2018

Here's a look at biotech stock trades, takeout targets and pot sellers that will dominate 2018.

3 More Stocks To Buy on Tax Reform

3 More Stocks To Buy on Tax Reform

Rent-A-Center, Foot Locker and AV Homes will get a nice holiday gift with the tax deal.

7 Hot Investing Bets to Make in Biotech

7 Hot Investing Bets to Make in Biotech

These favorite names in the volatile sector offer the potential for high rewards.

Amgen Teams Up With Cambridge Biotech Community To Select Two Startups To Receive Golden Tickets At LabCentral

Amgen Teams Up With Cambridge Biotech Community To Select Two Startups To Receive Golden Tickets At LabCentral

Amgen Golden Tickets Provide Innovative Startup Companies With Free Lab Space to Aid in Further Advancement of Their Science

7 Winners and Losers From Biggest Biotech Conference of 2017

7 Winners and Losers From Biggest Biotech Conference of 2017

Here are how some of the conference presenters are performing on the market Wednesday

TheStreet Quant Rating: B- (Buy)